In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.
News & Analysis: Nektar Therapeutics
The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.
Nektar Therapeutics' experimental opioid will finally get a long-awaited date with an FDA advisory committee -- and it probably won't go smoothly.
The company announced a new development plan with Bristol-Myers Squibb.
At least this pair of winners is getting cheerful in advance of the holidays.
Data presentations at a major scientific conference and the acquisition of another small biotech sparked investors' enthusiasm.
The biotech beat Wall Street estimates. But there's still a big unanswered question.
NKTR earnings call for the period ending September 30, 2019.
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
An analyst downgrade is only adding to the company's woes.